Dual Time Point FDG PET-MR Imaging Optimization for the Evaluation of Glioblastoma

• Status: Recruiting
• Trial end date: 0000-00-00
• Target enrollment: 20
• Participant gender: Both

Summary

The goal of this clinical research study is to compare the results during different scanning time points after a contrast drug is given for a FDG PET/CT. The contrast drug helps the researchers "see" the images more clearly.

• Phase: Phase 0
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Treatments: Fluorodeoxyglucose F18
• Last Updated: 2016-10-31

Criteria

Inclusion Criteria:

1. Pre-operative adult (>19 years of age) patients with biopsy proven (as opposed to being status post definitive surgical therapy) or highly suspected glioblastoma of the brain.

2. Cases without prior biopsy will be chosen based upon consensus of an MD Anderson faculty neuroradiologist and neurosurgeon for high probability of representing a glioblastoma

3. T1 post contrast lesion size greater than or equal to 10 mm

Exclusion Criteria:

1. Children

2. Definitive / gross total lesion resection

3. Prior brain cancer

4. Prior whole brain radiation

5. Known history of cerebrovascular disease, dementia or prior non-mild traumatic brain injury

6. Known allergy to FDG or gadolinium based contrast agents

7. Known diabetes or elevating fasting blood glucose (>180)

8. Pregnant women are excluded

9. Patients less than 19 years of age will be excluded.